Is diabetes mellitus a continuous spectrum?

Clinical Chemistry

Volumn 57, Issue 2, 2011, Pages 158-161

  Brooks Worrell, Barbara ^a,b   Palmer, Jerry P ^a,b  

^a Puget Sound Health Care System   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CLASSIFICATION; GENETIC ANALYSIS; HUMAN; IMMUNE SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATHOPHYSIOLOGY; SHORT SURVEY;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 79551479691     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.148270     Document Type: Short Survey

References (56)

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
2. McCance DR, Hanson RL, Pettitt DF, Bennett PH, Hadden DR, Knowler WC. Diagnosing diabetes mellitus: Do we need new criteria? Diabetologia 1997;40:247-55.
3. Zeitler P. Considerations regarding the diagnosis and treatment of childhood type 2 diabetes. Postgrad Med 2010;122:89-97.
4. Mohamadi A, Cooke DW. Type 2 diabetes mellitus in children and adolescents. Adolesc Med State Art Rev 2010;21:103-19.
5. Pinhas-Hamiel O, Zeitler P. Clinical presentation and treatment of type 2 diabetes in children. Pediatr Diabetes 2007;8(Suppl 9):16-27. (Pubitemid 350066644)
6. Lohmann T, Seissler J, Verlohren H-J, Schröder S, Rötger J, Dãhn K, et al. Distinct genetic and immunological features in patients with onset of IDDM before and after age 40. Diabetes Care 1997;20:524-9.
7. Libman IM, Sun K, Foley TP, Becker DJ. Thyroid autoimmunity in children with features of both type 1 and type 2 diabetes. Pediatr Diabetes 2008;9:266-71.
8. Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, Tuomi T, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008;57:1433-7.
9. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell B, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies but not the clinical phenotype help to identify type 1 1/2 diabetes in patients presenting with type 2 diabetes. Metabolism 2001;50:1008-13.
10. Ehses JA, Ellingsgaard H, Böni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch Physiol Biochem 2009;115:240-7.
11. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes. Diabetes Care 2008;31: S161-4.
12. Richardson SJ, Wilcox A, Bone AJ, Morgan NJ, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol [Epub ahead of print 2010 Apr 28].
13. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology 2009;24:325-31.
14. Böni-Schnetzler M, Ehses JA, Faulenbach M, Donath MY. Insulitis in type 2 diabetes. Diabetes Obes Metab 2008;10(Suppl 4):201-4.
15. Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J Immunol 1996;157:5668-74. (Pubitemid 126448991)
16. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JPP. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 2001;166:5265-70. (Pubitemid 32280744)
17. Roep BO, Kallan AA, Duinkerken G, Arden SD, Hutton JC, Bruining GJ, DeVries RRP. T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM. Diabetes 1995;44:278-83.
18. Roep BO. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes 1996;45:1147-56.
19. Mayer A, Fabien N, Gutowski MC, Dubois V, Gebuhrer L, Bienvenu J, et al. Contrasting cellular and humoral autoimmunity associated with latent autoimmune diabetes in adults. Eur J Endocrinol 2007;157:53-61.
20. Zavala AV, Fabiano de Bruno LE, Cardoso AI, Mota AH, Capucchio M, Poskus E, et al. Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Diabetologia 1992;35:1159-64.
21. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999;48:983-8.
22. Ismail H, Wotring M, Kimmie C, Au L, Palmer JP, Brooks-Worrell B. "T cell-positive antibodynegative" phenotypic type 2 patients, a unique subgroup of autoimmune diabetes [Abstract]. Diabetes 2007;56:A325.
23. Goel A, Chiu H, Felton J, Palmer JP, Brooks- Worrell B. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 2007;56:2110-5. (Pubitemid 47195836)
24. Verge CF, Gianani R, Kawasaki I, Yu LP, Pietropaolo F, Chase HP, Eisenbarth GS. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type 1 diabetes. J Autoimmun 1996;9:379-83. (Pubitemid 26226598)
25. Naserke HE, Ziegler A-G, Lampasona V, Bonifacio E. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 1998;161:6963-9.
26. Kawasaki E, Yu L, Rewers MJ, Hutton JC, Eisenbarth GS. Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes 1998;47:733-42.
27. Palmer JP. Predicting IDDM. Use of humoral immune markers. Diabetes Rev 1993;1:104-15.
28. Greenbaum CJ, Brooks-Worrell BM, Palmer JP, Lernmark A. Autoimmunity and prediction of insulin dependent diabetes mellitus. In: Marshal SM, Home PD, eds. Diabetes annual/8. Amsterdam: Elsevier; 1994. p 21-9.
29. Hosszúfalusi N, Yatay A, Rajczy K, Prohászka Z, Pozsonyi E, Horváth L, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003;26:452-7.
30. Murao S, Kondo S, Ohashi J, Fujii Y, Shimizu I, Fujiyama M, et al. Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA) - a 5-year follow-up of the Ehime study. Diabetes Res Clin Pract 2008;80:114-21.
31. Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, et al. SIC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci 2008;1150:256-9.
32. Seissler J, de Sonnaville JJJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998;41:891-7. (Pubitemid 28365974)
33. Borg H, Gottsäter A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adultonset diabetes. Diabetes 2002;51:1754-62.
34. Törn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohmé G, et al. Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000;85:4619-23.
35. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993;16:902-10.
36. Zinman B, Kahn SE, Hafner SM, O'Neill MC, Heise MA, Freed MI, and ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004;53:3193-200.
37. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48:150-7.
38. Chiu HK, Tsai EC, Juneja R, Stoever J, Brooks- Worrell B, Goel A, Palmer JP. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetes patients. Diabetes Res Clin Pract 2007;77:237-44.
39. Pang TTL, Narendran P. Addressing insulin resistance in type 1 diabetes. Diabet Med 2008;25:1015-24.
40. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661-7.
41. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, for the Diabetes Prevention Trial-Type 1 Study Group. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 2007;30:2314-20.
42. Bingley PJ, Mahon JL, Gale EAM, for the European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008;31:146-50.
43. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996;39:1005-29.
44. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6:158-66.
45. Maedler K, Dharmadhikari G, Schumann DM, Størling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 2009;9:1177-88.
46. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Selfert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-26.
47. Gleichmann H, Zörcher B, Greulich B, Gries FA, Henrichs HR, Betrams J, Kolb H. Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults. Diabetologia 1984;27(Suppl):90-2.
48. Törn C, Gupta M, Zake LN, Sanjeevi CB, Landin- Olsson M. Heterozygosity for MICA5.0/MICA5.1 and HLA-DR3-DQ2/DR4-DQ8 are independent genetic risk factors for latent autoimmune diabetes in adults. Hum Immunol 2003;64:902-9.
49. Sanjeevi CB, Gambelunghe G, Falorni A, Shtauvere-Brameus A, Kanungo A. Genetics of latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002;958:107-11.
50. Vatay A, Rajczy K, Pozsonyi E, Hosszúfalusi N, Prohászka Z, Füst G, et al. Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus. Immunol Lett 2002;84:109-15.
51. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-5.
52. Scott JL, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-5.
53. Boesgaard TW, Zilinskaite J, Vänttinen M, Laakso M, Jansson PA, Hammarstedt A, et al. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients - the EUGENE2 study. Diabetologia 2008;51:816-20.
54. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000;49:2201-7.
55. Grill V, Persson P-G, Carlsson S, Norman A, Alvarsson M, Ostensson CG, et al. Family history of diabetes in middle-aged Swedish men is a gender unrelated factor which associates with insulinopenia in newly diagnosed diabetes subjects. Diabetologia 1999;42:15-23.
56. Bonifacio E, Hummel M, Walter M, Schmid S, Ziegler AG. IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care 2004;27:2695-700.